Roche launches new test for human T-lymphotropic virus infections

Roche has announced the launch of its new Elecsys HTLV-I/II immunoassay, the latest addition to its portfolio of blood screening products.

The test is designed to help detect antibodies against Human T-lymphotropic virus I or II infection in donated blood and routine diagnostic samples. Its excellent sensitivity minimises the likelihood of missing early or chronic infections, thus cutting the risk of transmission.

Its high specificity facilitates clear and consistent interpretation of results at all disease stages, while minimising the need for re-testing. Additionally, the efficient test procedure allows a single test to be run within 18 minutes.

The test has been specifically designed for the needs of blood centres and clinical laboratories.

Roland Diggelmann, chief operating officer of Roche's diagnostics, said: "Roche is uniquely positioned to help blood centres improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions."

This comes after the firm agreed a new framework agreement with the Global Fund to provide the organisation with easier access to HIV diagnostic tools last month.